The domestic vaccine industry will enter a new round of development boom
Release time: 2011-09-19 & nbsp & nbsp & nbsp Source:
Business Club, September 16th News Recently，A foreign (overseas) investment announcement released by Shuanglu Pharmaceuticals，It is intended to contribute $ 2.0 million and Canadian PNU VAX Incorpolet cooperation，New Company (tentatively tentatively tentatively named PNUVAX SL biopharmaceuticals Inc.)，Mainly engaged in the development of vaccines and antibodies、Production and sales。
Guo Fanli, a researcher at the pharmaceutical industry of China Investment Consultant, pointed out，One paper announcement has attracted many eyeballs in the vaccine industry，The investment popularity of the vaccine industry is heating up again。Now some vaccine companies have put their attention to foreign markets and foreign companies，Try to cooperate with foreign companies is not uncommon。For example, Shuanglu invested 130 million yuan to Canada vaccine enterprise，In the past, there were also cooperation between Zhifei Biology and Merhadon and trying to acquire Dutch companies，and the cooperation project of Watson Biological and GSK。
Guo Fanli pointed out，Vaccine Industry Investment Large、High risk，Before the cooperation between domestic enterprises and foreign companies, there were success and failure。The current vaccine market，Foreign -funded companies occupy the main domestic market share，Therefore, in terms of product selection，Stake Sports BettingStake Sports BettingDomestic enterprises should increase the research and development and production of high -end vaccines、Increase the funds and R & D investment of vaccine products。Different relationships with the health of vaccine products and people's lives and health，Therefore, there are potential risks to invest in vaccine products。
At present, the competition in the vaccine industry is fierce，The problem of homogenization is also increasingly prominent。The cooperation between domestic vaccine manufacturers and foreign vaccine companies must adhere to the premise of "win -win"。Generally speaking，The most important reason for the choice of foreign -funded enterprises to cooperate with domestic enterprises is that they can directly use the market channels that domestic companies have built before to sell and promote their products，At the same time, domestic enterprises are closely related to local government departments，Save a lot of trouble to foreign companies，This is a part of the comparison of foreign -funded enterprises。
and domestic companies choose and well -known stake betting appstake online sports bettingforeign cooperation，On the one hand, you can learn the advanced management experience and service experience of multinational pharmaceutical groups，On the other hand, you can also use the high popularity of foreign companies to promote itself。And the reason why GSK failed to cooperate with Watson, Yunnan before is multiple aspects，For example, SFDA has not approved the Grammot Company's Memors-Mumps-rubella vaccine (MMR) in China，This is the direct cause of the collaboration between the two parties。
Guo Fanli said，"Twelfth Five -Year Plan" "Twelfth Five -Year Plan" of the Biomedical Industry Development is as soon as possible，Its core content has also been known by the industry，That is the development of gene drugs、protein drugs、Single clone antibody drugs、Therapeutic vaccine、Small molecular chemical drugs, etc.。Because of the "Plan", it is necessary to vigorously develop the therapeutic vaccine，Therefore, the domestic vaccine industry will enter a new round of development boom with the support of Planning。
Guo Fanli, a researcher at the pharmaceutical industry of China Investment Consultant, pointed out，One paper announcement has attracted many eyeballs in the vaccine industry，The investment popularity of the vaccine industry is heating up again。Now some vaccine companies have put their attention to foreign markets and foreign companies，Try to cooperate with foreign companies is not uncommon。For example, Shuanglu invested 130 million yuan to Canada vaccine enterprise，In the past, there were also cooperation between Zhifei Biology and Merhadon and trying to acquire Dutch companies，and the cooperation project of Watson Biological and GSK。
Guo Fanli pointed out，Vaccine Industry Investment Large、High risk，Before the cooperation between domestic enterprises and foreign companies, there were success and failure。The current vaccine market，Foreign -funded companies occupy the main domestic market share，Therefore, in terms of product selection，Stake Sports BettingStake Sports BettingDomestic enterprises should increase the research and development and production of high -end vaccines、Increase the funds and R & D investment of vaccine products。Different relationships with the health of vaccine products and people's lives and health，Therefore, there are potential risks to invest in vaccine products。
At present, the competition in the vaccine industry is fierce，The problem of homogenization is also increasingly prominent。The cooperation between domestic vaccine manufacturers and foreign vaccine companies must adhere to the premise of "win -win"。Generally speaking，The most important reason for the choice of foreign -funded enterprises to cooperate with domestic enterprises is that they can directly use the market channels that domestic companies have built before to sell and promote their products，At the same time, domestic enterprises are closely related to local government departments，Save a lot of trouble to foreign companies，This is a part of the comparison of foreign -funded enterprises。
and domestic companies choose and well -known stake betting appstake online sports bettingforeign cooperation，On the one hand, you can learn the advanced management experience and service experience of multinational pharmaceutical groups，On the other hand, you can also use the high popularity of foreign companies to promote itself。And the reason why GSK failed to cooperate with Watson, Yunnan before is multiple aspects，For example, SFDA has not approved the Grammot Company's Memors-Mumps-rubella vaccine (MMR) in China，This is the direct cause of the collaboration between the two parties。
Guo Fanli said，"Twelfth Five -Year Plan" "Twelfth Five -Year Plan" of the Biomedical Industry Development is as soon as possible，Its core content has also been known by the industry，That is the development of gene drugs、protein drugs、Single clone antibody drugs、Therapeutic vaccine、Small molecular chemical drugs, etc.。Because of the "Plan", it is necessary to vigorously develop the therapeutic vaccine，Therefore, the domestic vaccine industry will enter a new round of development boom with the support of Planning。
